Aerosolizable pharmaceutical formulation for fungal infection therapy
AssigneeNektar Therapeutics
InventorsJeffry G. Weers, Thomas E. Tarara, Michael A. Eldon, Rangachari Narasimhan
Life of this patent
Estimating the term…
Abstract
A method of treating and/or providing prophylaxis against a pulmonary fungal infection comprises delivering an aerosolized pharmaceutical formulation comprising an antifungal agent to the lungs. The method comprises determining the minimum inhibitory concentration of the antifungal agent for inhibiting pulmonary fungal growth. A sufficient amount of the pharmaceutical formulation is administered to maintain for a period of time a target antifungal agent lung concentration that is greater than the determined minimum inhibitory concentration. In one version, the antifungal agent is amphotericin B.
Claims97
A method of treating and/or providing prophylaxis against a pulmonary fungal infection, the method comprising:
- determining the minimum inhibitory concentration of an antifungal agent for inhibiting pulmonary fungal growth;
- and
- administering an aerosolized pharmaceutical formulation comprising the antifungal agent to the lungs of a patient;
- wherein a sufficient amount of the pharmaceutical formulation is administered to maintain for at least one week a target antifungal agent lung concentration of at least two times the determined minimum inhibitory concentration.
A method of treating and/or providing prophylaxis against a pulmonary fungal infection, the method comprising:
- administering an aerosolized pharmaceutical formulation comprising amphotericin B to the lungs of a patient;
- wherein a sufficient amount of the pharmaceutical formulation is administered to maintain for at least one week a target amphotericin lung concentration of at least 5 μg/g.
A method of treating or providing prophylaxis against a pulmonary lung infection, the method comprising:
- determining the minimum inhibitory concentration of an antifungal agent for inhibiting pulmonary fungal growth;
- and
- administering at least once per week an aerosolized pharmaceutical formulation comprising the antifungal agent to the lungs of a patient;
- wherein the amount of the pharmaceutical formulation administered is sufficient to maintain for at least three weeks a target antifungal agent lung concentration that is greater than the determined minimum inhibitory concentration.
A method of treating or providing prophylaxis against a pulmonary lung infection, the method comprising:
- administering at least once per week an aerosolized pharmaceutical formulation comprising amphotericin B to the lungs of a patient;
- wherein the amount of the pharmaceutical formulation administered is sufficient to maintain for at least three weeks a target amphotericin B lung concentration that is greater than the 4 μg/g.
A method of providing prophylaxis against a pulmonary lung infection, the method comprising:
- determining the minimum inhibitory concentration of an antifungal agent for inhibiting pulmonary fungal growth;
- administering an aerosolized pharmaceutical formulation comprising the antifungal agent to the lungs of a patient, wherein the amount of the pharmaceutical formulation administered is sufficient to achieve a target antifungal agent lung concentration that is greater than the determined minimum inhibitory concentration;
- thereafter administering an immunosuppressive agent to the patient for a period of time;
- and
- maintaining the target antifungal agent lung concentration throughout the period of time.
A method of providing prophylaxis against a pulmonary lung infection, the method comprising:
- administering an aerosolized pharmaceutical formulation comprising amphotericin B to the lungs of a patient, wherein the amount of the pharmaceutical formulation administered is sufficient to deliver at least 5 mg of amphotericin B to the lungs per week;
- thereafter administering an immunosuppressive agent to the patient for a period of time;
- and
- administering at least 5 mg of amphotericin B to the lungs per week throughout the period of time.
A method of treating or providing prophylaxis against a pulmonary lung infection, the method comprising:
- delivering an aerosolized pharmaceutical formulation comprising from 5 mg to 10 mg of amphotericin B to the respiratory tract of a patient once per week for a period of at least two weeks.
A unit dose receptacle comprising an aerosolizable pharmaceutical formulation for delivering from 5 mg to 10 mg of amphotericin B when aerosolized.
Dependencies are inferred from the claim text.